Ocugen Q2 Results: Earnings call set for Aug 6 to discuss financials

Ocugen, Inc., a biotechnology company developing gene therapies for blindness diseases, will host a conference call and live webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide a business update. The company will issue a pre-market earnings announcement on the same day. This event provides investors with direct access to management’s commentary on the company’s financial performance and strategic progress in advancing its modifier gene therapy platform for inherited retinal diseases and other causes of blindness.

The conference call is scheduled for August 6, 2026, at 8:30 a.m. ET. Attendees may participate using the provided dial-in numbers or by accessing the live webcast through the events section of the Ocugen investor site. A replay of the call and an archived webcast will be available on the Ocugen investor site following the event.

Conference Call Details

Detail	Information
Date	August 6, 2026
Time	8:30 a.m. ET
Dial-in (U.S.)	(800) 715-9871
Dial-in (International)	(646) 307-1963
Conference ID	2222566
Webcast	Ocugen Investor Site

Ocugen is advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. The company’s breakthrough modifier gene therapy platform is designed to address underlying disease biology by restoring balance across multiple gene networks, differing from traditional gene therapies that target single gene mutations.

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that may cause actual events or results to differ materially from current expectations. Risks are described in the company’s periodic filings with the Securities and Exchange Commission (SEC). Forward-looking statements speak only as of the date of this press release, and the company assumes no obligation to update them except as required by law.

For investor inquiries, contact Candice Masse at astr partners. For media inquiries, contact Chris Clark at Ocugen, Inc.

Ocugen, Inc. has signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to license OCU400, a novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region. The agreement grants exclusive rights to the partners and includes financial terms such as upfront license fees, development milestones, sales milestones, and royalties. Ocugen will also manufacture and supply the commercial product under a related supply agreement.

Under the terms of the term sheet, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to $4 million. The company is entitled to sales milestone payments of up to $255 million, in addition to a 22% royalty on net sales generated by its partners. The definitive agreement is expected to be executed within the next 90 days.

Financial Terms

Component	Amount/Rate
Upfront and near-term milestones	$4 million
Sales milestones	$255 million
Royalty on net sales	22%

RP is a leading cause of inherited vision loss globally, with notable prevalence across the MENA region. The partnership aims to address the significant unmet medical need for this condition in the area. Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development, with a topline readout expected in 1Q 2027 and a BLA submission to follow.

"This step forward represents an important milestone in our effort to advance OCU400 regional partnership strategy," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. He emphasized that the partnership expands the company's ability to bring a potential one-time treatment to a region with high RP prevalence and significant unmet need.

Dr. Islam Zayed, CEO & Co-founder of Roots Pharmaceutical, highlighted the strategic importance of bringing innovative gene therapies to MENA patients. He stated that OCU400 builds on the company's legacy of delivering rare disease therapies and aims to decrease disease burden in the region.